F4 FundFund
TeamPortfolioRaiseChampionsEssays
Sign in
Investment ThesisInvestment TeamF4 Research BriefSelected PortfolioRecent UpdatesFrequent co-investorsSimilar Firms
Warm Fund

11.2 Capital

112capital.com · San Francisco

“We invest in technically sophisticated founding teams solving breakthrough problems in deep-tech. We believe the next generation of transformational companies will be built by scientists and engineers with deep domain expertise tackling problems at the frontier of AI, cybersecurity, quantum, robotics, space, synthetic biology, and bioengineering.”

$500K – $3M
Check Size
Leads
Lead Tendency
~2 Weeks
Timeline
01Investment Thesis

We provide patient capital and technical partnership to help these teams achieve escape velocity.

Exclusion Criteria

We avoid pure consumer social networks, services-heavy models, non-technical founding teams, and companies lacking deep technical/scientific bottlenecks. We are not interested in businesses that don't require significant R&D capability or breakthrough innovation.

02Investment Team
SZ
Shelley Zhuang
Founder and Managing Partner
AC
Andy Chou
Partner
DD
David Dorsey
Partner
JS
Jacob Smith
Principal
PG
Pramod Gosavi
Principal
03F4 Research Brief

11.2 Capital Research Document

Investment Thesis & Philosophy

11.2 Capital, named after Earth's escape velocity (11.2 km/s), is a deep-tech venture capital firm founded in 2013-2014 and based in San Francisco, California. The firm's core philosophy centers on backing technically sophisticated founding teams solving breakthrough problems in the most challenging technological domains. The firm's name reflects their mission: helping companies achieve "escape velocity" to reach the next level of technological impact and scale.

The fund explicitly positions itself as an investor for technically deep founding teams who require partners capable of engaging with complex product development, R&D, and scientific challenges. Unlike most early-stage venture firms, 11.2 Capital has built a reputation for bioengineering expertise—a rare concentration among early-stage tech funds. This technical depth allows them to evaluate and support companies tackling problems at the frontier of science and engineering.

Deep-Tech Focus Areas

11.2 Capital invests exclusively across interconnected deep-tech sectors:

Primary Technology Verticals:

  • Artificial Intelligence & Machine Learning - Both AI infrastructure (like Anyscale's distributed computing framework) and AI applications in specialized domains
  • Cybersecurity & Defense - Security infrastructure, authentication, attack surface management (JupiterOne portfolio company)
  • Quantum Computing - Quantum technology development and applications
  • Robotics & Automation - Robotic systems, imitation learning (Covariant in portfolio), and physical automation
  • Space Technology - New space ventures and space infrastructure
  • Synthetic Biology & Bioengineering - Computational therapeutics, genetic engineering, biotech applications (strong focus relative to other early-stage funds)
  • Life Sciences & Healthcare Tech - Digital health applications and biotech (multiple portfolio companies including Hinge Health)

Cross-Cutting Technical Interests:

  • Distributed systems and infrastructure (Ray/Anyscale)
  • Cyber asset management and security
  • Autonomous systems (formerly Cruise)
  • Computational biology and data platforms

Investment Stage & Check Size

11.2 Capital is firmly positioned as an early-stage focused investor, with the vast majority of investments in Pre-Seed and Seed rounds.

Stage Distribution:

  • Seed: 12 investments at average check size of $5.86M
  • Series A: 9 investments at average check size of $14.2M
  • Series B+: Selective follow-ons (less common)

Typical Check Size: $500,000 - $3,000,000

  • Pre-Seed: $500K-$1.5M (first checks for deeply technical teams)
  • Seed: $1.5M-$3M (for teams with prototype/MVP and initial validation)
  • Series A: Up to $3M+ as participation or lead (when appropriate to their thesis)

The fund typically backs 2-5 new companies per year, reflecting a highly selective approach. Investment frequency data from 2017-2024 shows steady 2-4 new first-time investments annually, with strategic follow-on rounds comprising additional annual deployment.

Lead Tendency

Strong lead tendency for early-stage rounds. 11.2 Capital leads pre-seed and seed rounds when they identify strong technical founding teams aligned with their thesis. They also participate opportunistically in Series A and later rounds for portfolio company follow-ons. Their concentrated portfolio model and deep technical due diligence suggests they maintain meaningful board/advisor influence in portfolio companies, though they take a true investor (non-board seat) approach.

Co-investors frequently include Amplify Partners, Emergence Capital, Polaris Partners, and other tier-one early-stage focused VCs. Their position in the market suggests they lead rounds in their core competency areas (deep-tech, biotech, AI infrastructure) while participating in broader early-stage rounds when thesis-aligned.

Recent Activity & Fund Status

11.2 Capital appears to be in active deployment phase, though with reduced pace reflecting both venture market conditions and their selective approach.

Recent First-Time Investments (2024):

  • Leen (Seed, $6.85M, co-led with Inner Loop Capital) - appears to be AI/workforce related
  • Thea Energy (Series A, $3.73M, co-led with Prelude Ventures) - energy technology, clean energy focus

Recent Follow-On Investments (2024):

  • Noetik (Series A follow-on, $2.84M, July 2024) - Series A participation
  • Mantle (Series C follow-on, $8.62M, July 2024)
  • Coalesce (Series B follow-on, $1.41M, March 2024)

Portfolio Company Exits (Recent):

  • Mantle: Acquired November 2025 (Series B follow-on investment)
  • Hinge Health: IPO May 2025 on NYSE at $792M market cap (Series A investment from July 2017)
  • Odyssey Aviation: Acquired January 2025

Fund Status: Actively deploying with selective new deal flow. Recent activity suggests fund has capital available and is carefully deploying into thesis-aligned opportunities. No recent announcements of new fund closes, suggesting they are likely in the deployment phase of an existing fund.

Portfolio Highlights & Track Record

11.2 Capital has built an impressive 56-company portfolio over 12 years with exceptional outcomes including 3 unicorns (Anyscale, JupiterOne, Forter), 3 IPOs (Hinge Health, Ginkgo Bioworks, Arbor Realty Trust), and 9 acquisitions including major exits like Mantle (November 2025), Cruise (autonomous vehicles), and Deep Genomics (AI genetic medicine).

Team & Expertise

11.2 Capital operates as a lean, technically sophisticated partnership with 5 professionals. The partnership structure includes founders Shelley Zhuang, Andy Chou, David Dorsey, plus principals Jacob Smith and Pramod Gosavi. The team is distributed across Las Vegas, Palo Alto, and San Francisco, providing proximity to investor networks and entrepreneurial hubs.

Decision Process & Investment Approach

Decision-Making Structure: Partnership model with collaborative investment committee approach. The lean team suggests founders experience relatively streamlined decision processes with quick partner alignment.

Diligence Approach:

  • Technical deep-dive on R&D complexity and feasibility
  • Assessment of founding team's technical depth and execution capability
  • Evaluation of market size and potential technological impact
  • Network and reference calls with technical advisors and domain experts
  • Limited bureaucracy due to small team size

Typical Investment Timeline: 2-4 weeks for qualified technical founders

Board Involvement: The firm does not take formal board seats, instead positioning themselves as strategic technical advisors and capital partners. This allows deep engagement without governance overhead.

Geographic Focus

Primary Investment Geography: United States, with concentration in San Francisco Bay Area, Palo Alto, Los Angeles, NYC, and Seattle. Secondary markets include United Kingdom (2 investments) and Canada (1 investment), indicating strong US concentration with selective international exposure for exceptional companies.

Founder Preferences & Investment Criteria

Ideal Founder Profile:

  • Technically deep - PhD or equivalent depth in computer science, physics, biology, engineering, or related discipline
  • Problem-obsessed - Solving a specific technical bottleneck or breakthrough challenge
  • Team composition - Technical founders preferred; mix of scientific/engineering expertise with business execution capability
  • Prior track record - Founding experience, research publications, or successful technical exits valued
  • Receptive to partnership - Willing to engage deeply with investors on technical strategy and roadmap

What They Avoid:

  • Consumer social applications
  • Services-heavy business models
  • Non-technical founding teams
  • Markets without deep technical/scientific bottlenecks
  • Applications that don't require significant R&D capability
04Selected Portfolio
Biotech & Life Sciences
Ginkgo Bioworks·Deep Genomics·Coalesce·Loop Genomics
Developer Tools & Infrastructure
MightyMeld
E-commerce & Marketplaces
The RealReal·Noetik
Energy & Power
Thea Energy
Enterprise Software
Anyscale·Avaamo
Fintech & Payments
Mantle
Healthcare & Digital Health
Hinge Health·CancerNavigator
Robotics & Automation
Covariant
Security & Cybersecurity
JupiterOne·Forter·StrikeReady·Leen
Travel & Hospitality
Odyssey Aviation
Other
Cruise·Kindred Group
Open the full portfolio→
05Recent Updates

Fresh signals from public announcements, essays, and portfolio activity.

See full activity (5) →
Portfolio company Anyscale was acquired by Nscale for $1.65 billion to build a full-stack AI hyperscaler.
EXIT·techcrunch.com
JUL 30, 2026
Led investment in CancerNavigator, a patient navigation service for cancer care management.
INVESTMENT·oncologyventures.substack.com
FEB 2026
Portfolio company Mantle was acquired by Angstrom Group, expanding industrial 3D printing tooling capabilities.
EXIT·metal-am.com
NOV 2025
Hinge Health completed IPO on NYSE at ~$3B valuation, with 11.2 Capital exiting ~8% stake.
EXIT·techcrunch.com
MAY 22, 2025
Portfolio company Odyssey Aviation was acquired by Tallvine Partners.
EXIT·globenewswire.com
JAN 2025
06Frequent co-investors
AP
Amplify Partners
Both backed 2 of the same companies
Covariant, Anyscale
CC
Cota Capital
Both backed 2 of the same companies
Forter, Anyscale
MV
Monta Vista Capital
Both backed 2 of the same companies
StrikeReady, Avaamo
NC
NewView Capital
Both backed 2 of the same companies
Hinge Health, Forter
Find the investors for your round→
07Similar Firms
LC
Lux Capital
$100K – $100M · Pre-Seed · Seed
→
UV
United Ventures
$1M – $8M · Seed · Series A
→
1F
1517 Fund
$50K – $1M · Pre-Seed · Seed
→
HC
Human Capital
$250K – $200M · Pre-Seed · Seed
→
LV
Lightspeed Venture Partners
$1M – $300M · Seed · Series A
→
Quick Reference
Check Size
$500K – $3M
Stages
Pre-Seed · Seed · Series A
Decision
Partnership · ~2 Weeks
Warm Intro
Not Required
Involvement
Advisor
Location
San Francisco
Sector Focus
Aerospace & DefenseBiotech & Life SciencesRobotics & AutomationDeveloper Tools & InfrastructureSecurity & Cybersecurity
Models
Deep-TechBiotechAI InfrastructureRoboticsCybersecuritySpace TechSynthetic Biology
Technology
AI/MLQuantum ComputingDistributed Systems
See all Aerospace & Defense investors →See all Biotech & Life Sciences investors →See all Robotics & Automation investors →
Visit 112capital.com ↗

See how 11.2 Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Focus Areas
Aerospace & DefenseBiotech & Life SciencesRobotics & AutomationDeveloper Tools & InfrastructureSecurity & Cybersecurity

See how 11.2 Capital matches your startup

Get a personalized match report in minutes.

Get Your Match Report
Is this your firm? Claim your profile
F4 Intelligence Report · Last Researched August 1, 2026F4 Research Engine